Hypolipidemic effects of α, β, and γ-alkylaminophenone analogs in rodents
摘要:
A number of N-substituted beta-alkylaminophenone derivatives including two alpha- and two gamma-alkylaminophenone analogs were synthesized and investigated for hypolipidemic activity in mice at 8 mg/kg/day ip. Most of these analogs were found to be significantly more active than lovastatin and clofibrate. N-Phenylpiperazinopropiophenone 16 was one of the best derivatives, lowering serum cholesterol levels 41% and serum triglyceride levels 48% after 16 days of drug administration in CF1 mice. In Sprague-Dawley rats, N-phenylpiperazinopropiophenone at 8 mg/kg/day orally also demonstrated more potent hypolipidemic activity than clofibrate, gemfibrozil, and lovastatin at their therapeutic dosage. It significantly reduced tissue cholesterol and triglyceride levels in the aorta wall tissue and lowered the cholesterol and triglyceride levels in chylomicron, very low density lipid (VLDL) and low density lipid (LDL) fractions, while it significantly elevated the cholesterol levels in high density lipid (HDL) fraction. This compound also proved to be active in lowering both cholesterol and triglyceride levels in hyperlipidemic mice and rats induced with atherogenic diet. In vitro liver acetyl coenzyme A (CoA) synthetase, 3-hydroxy-3-methyl glutaryl (HMG) CoA reductase, acyl CoA cholesterol acyl transferase (ACAT), sn-glycerol-3-phosphate acyltransferase, phosphatidylate phosphohydrolase, and hepatic lipoprotein lipase activities were significantly inhibited by N-phenylpiperazinopropiophenone from 25 to 100 mu M.
Some (piperidinomethylene)bis(phosphonicacid) derivatives were prepared and their activity to inhibit a rise in serum calcium induced by parathyroid hormone in thyroparathyroidectomised rats was evaluated. Several (4-alkylidene-, 4,4-dialkyl-, or 4-alkyl-4-halopiperidinomethylene)bis(phosphonicacid) derivatives showed considerable inhibitory activity. But compounds having aromatic and polar substituents
Novel 3-phenylprop-2-ynylamines as inhibitors of mammalian squalene epoxidaseElectronic supplementary information (ESI) available: Proton NMR spectra for the intermediate piperidines 56–60 and acetylenes 63-81 and 85,86. See http://www.rsc.org/suppdata/ob/b2/b209165h/
作者:David L. Musso、Morris J. Clarke、James L. Kelley、G. Evan Boswell、Grace Chen
DOI:10.1039/b209165h
日期:2003.1.30
The synthesis of a novel series of 3-phenylprop-2-ynylamines as selective mammalian squalene epoxidase inhibitors is described. Structure–activity relationship studies led to the discovery of compound 19, 1-[3-(3,5-dichlorophenyl)prop-2-ynyl]-3-methylpiperidine hydrochloride with an IC50 of 2.8 ± 0.6 µM against rat liver squalene epoxidase. Against 23 strains of fungal squalene epoxidase compound 19 was found to be inactive.
Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as
申请人:Pfizer, Inc.
公开号:US06107329A1
公开(公告)日:2000-08-22
Compounds of Formula (1) wherein R.sub.6 is carboxy, (C.sub.1 -C.sub.8)alkoxycarbonyl, benzyloxycarbonyl, C(O)NR.sub.8 R.sub.9 or C(O)R.sub.12 as glucogen phosphorylase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals.
Synthesis and cytotoxic activity of α-santonin amino-derivatives
作者:S. G. Klochkov、S. V. Afanas’eva、A. N. Pushin、G. K. Gerasimova、N. K. Vlasenkova、Yu. N. Bulychev
DOI:10.1007/s10600-010-9499-3
日期:2009.11
Previously unknown amino-derivatives of the natural sesquiterpene lactone α-santonin were synthesized. The activity of the products against several human tumor-cell lines was studied.
未知氨基酸衍生物的天然倍半萜内酯α-山道年被合成。研究了产物对几种人肿瘤细胞株的活性。
Studies on pyrrolidinones. Synthesis of some bioisosteres of 3,3,5-trimethylcyclohexyl pyroglutamate
作者:Benoǐt Rigo、Claude Laruelle
DOI:10.1002/jhet.5570340142
日期:1997.1
The synthesis of new N-(4-chlorobenzyl) and N-(4-chlorobenzoyl)pyroglutamic esters and amids whose the structure conserves the main structural features of the cholesterol lowering agent crilvastatin is described.